366 the Impact and the Prevalence of Nonalcoholic Fatty Liver Disease on Chronic Hepatitis B

Pirvulescu, Iuliana; Gheorghe, L.; Suciu, Sanda; Gheorghe, Cristian; Diculescu, Mircea

doi:10.1016/s0168-8278(10)60368-6

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The follow-up period was set as 300 days after the index date. Patients were selected based on eligibility criteria with the help of the Clinical Looking Glass (CLG, Streamline Health, Atlanta, GA, USA), which is a user-friendly software that can help clinical researchers navigate through electronic medical records (EMRs) and select cohorts of eligible patients [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Katamreddy

Kataria

et al. 2021

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background Limited evidence-based therapies exist for the management of heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in patients with systolic heart failure (HFrEF) and type-2-diabetes mellitus (T2DM) is associated with improved cardiovascular (CV) and renal outcomes. Objective We sought to examine whether there is an association of SGLT2i use with improved CV outcomes in patients with HFpEF. Patients and methodsWe conducted a single-center, retrospective review of patients with HFpEF and T2DM. The cohort was divided into two groups based on prescription of a SGLT2i or sitagliptin. The primary outcome was heart failure hospitalization (HFH); secondary outcomes were all-cause hospitalization and acute kidney injury (AKI). Results After propensity score matching, there were 250 patients (89 in the SGLT2i group, 161 in the sitagliptin group), with a mean follow-up of 295 days. Univariate Cox regression analysis showed that the SGLT2i group had a reduced risk of HFH versus the sitagliptin group (hazard ratio (HR) 0.13; 95% confidence interval (CI) (0.05-0.36); p < 0.001). The SGLT2i group had a decreased risk of all-cause hospitalization (HR 0.48; 95% CI (0.33-0.70); p < 0.001) and SGLT2i had a lower risk of AKI (HR 0.39; 95% CI (0.20-0.74); p = 0.004). Conclusions The use of SGLT2is is associated with a reduced incidence of HFH and AKI in patients with HFpEF and T2DM.

show abstract

Section: Methodsmentioning

confidence: 99%

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Katamreddy

Kataria

et al. 2021

Drugs - Real World Outcomes

View full text Add to dashboard Cite

show abstract

“…Research has shown that the prevalence of liver steatosis in individuals with HBV infection varies from 14.0% to 70.0% [1]. The prevalence of nonalcoholic fatty liver disease (NAFLD) in those with HBV is believed to be influenced by host factors, primarily components of Metabolic Syndrome (MS) such as diabetes mellitus, dyslipidemia, abdominal obesity, and arterial hypertension [2][3][4]. Whether hepatic steatosis affects viral load and treatment response in HBV patients remains debatable [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…Whether hepatic steatosis affects viral load and treatment response in HBV patients remains debatable [5,6]. However, several studies have provided evidence that in patients with chronic hepatitis B, components of Metabolic Syndrome (MS) correlate with the onset of NAFLD and can lead to liver fibrosis [2]. Furthermore, the MS, which encompasses NAFLD, is also considered pivotal in the progression of hepatic cirrhosis in patients with chronic hepatitis B [7].…”

Section: Introductionmentioning

confidence: 99%

Haptoglobin 2-2 Genotype is Related to the Severity of Liver Damage in Hepatitis B Patients with Liver Steatosis

You,

Lu,

Yan

et al. 2023

Discovery Medicine

View full text Add to dashboard Cite

Background: The Haptoglobin (Hp) genotypes have been linked to immune diseases and play a significant role in metabolic diseases. This study aimed to analyze the correlation between Hp gene polymorphism and the severity of hepatitis B accompanied by liver steatosis. Methods: A total of 182 with Hepatitis B and concurrent hepatic steatosis were included in the study. Clinical biochemical indices for each participant were recorded. DNA was extracted from peripheral blood leukocytes for globin genotyping. Of these participants, 128 underwent biopsy from which histological data were collected. Results: Subjects with hepatitis B and hepatic steatosis carrying the Hp 2-2 genotype exhibited elevated alanine transaminase (ALT), c-glutamyl transferase (GGT), and aspartate amino transferase (AST) levels. In contrast, high-density lipoprotein (HDL) levels and the copy number of Hepatitis B Virus (HBV)-DNA were significantly reduced in those with the Hp 2-2 genotype (p < 0.05). Furthermore, individuals processing the Hp 2-2 genotype demonstrated a heightened hepatitis score and advanced fibrosis stage (p < 0.05). Notably, the Hp 2-2 genotype was independently associated with increased inflammation (odds ratio (OR) = 7.059, p < 0.001) and progressive fibrosis (OR = 3.05, p < 0.022). Conclusions: The Hp 2-2 genotype is significantly associated with increased severity in cases of hepatitis B with coexisting hepatic steatosis.

show abstract

366 the Impact and the Prevalence of Nonalcoholic Fatty Liver Disease on Chronic Hepatitis B

Cited by 2 publications

References 0 publications

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Haptoglobin 2-2 Genotype is Related to the Severity of Liver Damage in Hepatitis B Patients with Liver Steatosis

Contact Info

Product

Resources

About